Phase 3 trial for tricaprilin in Alzheimer’s dementia
Part of Brain & nervous system, Mental health clinical trials.
This trial tests tricaprilin to see if it helps slow or improve symptoms in people with probable Alzheimer’s dementia. It looks for specific brain changes, blood test results, and gene status that support an Alzheimer’s diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Alzheimer’s dementia that doctors think is “probable” based on standard criteria
- Your memory/cognition test score (MMSE) is between 14 and 24
- You had a brain MRI scan within the last 12 months that fits Alzheimer’s
- Blood tests support Alzheimer’s (Aβ42/40 and/or pTau217 results)
- Your genetic test shows you have the APOE4 type
- You’re already taking certain dementia medicines (like donepezil, galantamine, rivastigmine, memantine) or GV-971/other cognition-related medicines for long enough without dose changes planned
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
This study tests an investigational drug, ARO-MAPT-SC, which targets a protein involved in Alzheimer's disease. It is for people with early Alzheimer's to see if the drug is safe and can slow the disease.
This trial tests a treatment targeting tau protein buildup in the brain for people with early Alzheimer's. You may join if you have memory or thinking changes but are still living independently, and brain scans show both amyloid and tau clumps.
This Phase 3 study looks for blood/brain “biomarkers” linked to aging, memory changes, and early brain degeneration. It may help researchers better identify who is at risk and how biology relates to thinking and memory, using brain scans and thinking tests.
This study tests a sequence of treatments to see if they can help people with Alzheimer's disease or mild cognitive impairment. It aims to slow down memory decline and improve daily function.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.